Retraction Note to: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients(Medical Oncology, (2014), 31, 251, DOI 10.1007/s12032-014-0251-x);A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients

Medical Oncology

Volumn 31, Issue 12, 2014, Pages 1-6

  Yao, Jun ^a   Wang, Jian yao ^b   Liu, Yi ^c   Wang, Bin ^b   Li, Ying xue ^a   Zhang, Ru ^a   Wang, Li Sheng ^a   Liu, Lei ^b  

^a JINAN UNIVERSITY   (China)

^b SHENZHEN CHILDREN'S HOSPITAL   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Adverse event; Everolimus; Pancreatic neuroendocrine tumors; Progression free survival

Indexed keywords

EVEROLIMUS; PLACEBO; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEILITIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; FATIGUE; FEVER; GINGIVITIS; GLOSSITIS; HAZARD RATIO; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMATITIS; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIROLIMUS; SURVIVAL RATE;

EID: 84919906810     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0661-4     Document Type: Erratum

References (16)

1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727–33. doi:10.1093/annonc/mdn351.
2. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14(5):456–67. doi:10.1634/theoncologist.2008-0259.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. doi:10.1200/JCO.2007.15.4377.
4. Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case–control study. Int J Cancer. 2011;128(5):1179–86. doi:10.1002/ijc.25426.
5. Lam KY, Lo CY. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients. Am J Gastroenterol. 1998;93(8):1232–5. doi:10.1111/j.1572-0241.1998.401_w.x.
6. Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol/Hematol. 2009;72(2):110–24. doi:10.1016/j.critrevonc.2009.01.008.
7. Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 2010;17(1):R75–90. doi:10.1677/ERC-09-0108.
8. Clark OH, Benson AB 3rd, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7(7):712–47.
9. Granberg D. Investigational drugs for neuroendocrine tumours. Expert Opin Investig Drugs. 2009;18(5):601–8. doi:10.1517/13543780902850432.
10. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86(6):944–8.
11. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004;27(5):485–8.
12. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245–55. doi:10.1200/JCO.2008.21.5988.
13. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76. doi:10.1200/JCO.2009.24.2669.
14. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–8. doi:10.1200/JCO.2008.16.7858.
15. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med. 2011;364(6):514–23. doi:10.1056/NEJMoa1009290.
16. Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, et al. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol. 2012;42(10):903–11. doi:10.1093/jjco/hys123.